Related references
Note: Only part of the references are listed.The immunobiology of MIF: function, genetics and prospects for precision medicine
Insoo Kang et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach
Michal Haran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
IMMU-115 (HUMANIZED ANTI-CD74 ANTIBODY) FOR SUBCUTANEOUS (SC) ADMINISTRATION: A PHASE IB STUDY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
D. J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Beth A. Christian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
Peter Martin et al.
LEUKEMIA & LYMPHOMA (2015)
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
Jonathan L. Kaufman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression
Daniela Froelich et al.
ARTHRITIS RESEARCH & THERAPY (2012)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
